DLA Piper Advises CGI Windows & Doors Holdings, Inc. in US$111 million deal with PGT, Inc.

DLA Piper represented CGI Windows & Doors Holdings, Inc. (CGI), a portfolio company of Cortec Group Fund IV, LP and a premier manufacturer of hurricane-impact-resistant windows and doors, in the sale of its business to PGT, Inc. (NYSE: PGTI), a leading manufacturer and supplier of residential impact-resistant windows and doors. The transaction is expected to close in September of 2014, subject to customary closing conditions.

More >>

Tags:  DLA Piper

L Brands, Inc. $1 Billion Revolving Credit Facility

Davis Polk advised L Brands, Inc. in connection with its $1 billion amended and restated secured revolving credit facility. This new facility replaces an existing $1 billion secured revolving credit facility, and includes a right for certain of L Brands’ non-U.S. subsidiaries to borrow and obtain letters of credit, which borrowings and letters of credit will be guaranteed by L Brands and its material U.S. subsidiaries, and a right for L Brands to increase the commitments under the facility by $500 million subject to the consent of the lenders providing such additional commitments. Under the new facility L Brands and certain of such foreign subsidiaries may borrow and obtain letters of credit in U.S. dollars and, subject to specified limitations as to the amount of each such currency, Canadian dollars and pounds sterling, and, subject to the consent of the relevant lenders, to add additional currencies and subsidiary borrowers.

More >>

Willkie Advises GFI Group and GFI Management Group on Strategic Transactions with CME Group Valued at $820 Million

On July 30, it was announced that Willkie client GFI Group Inc., a leading intermediary and provider of trading technologies and support services to the global OTC and listed markets, entered into definitive agreements with CME Group, the world’s leading and most diverse derivatives marketplace, to create value for their respective stockholders through a two-step transaction. The total deal value is approximately $820 million including outstanding debt. In the first step, CME Group will acquire the Trayport and FENICS subsidiaries of GFI Group by first acquiring all of the outstanding shares of GFI Group in exchange for $4.55 per share in CME Group Class A Common Stock.

More >>

Tags:  Willkie Farr & Gallagher LLP

Shearman & Sterling Advises Lead Arrangers on $5 Billion Financing for Abbott Laboratories

Shearman & Sterling advised Merrill Lynch, Pierce, Fenner & Smith Incorporated, Barclays Bank Plc, J.P. Morgan Securities LLC and Morgan Stanley Senior Funding, Inc. as joint lead arrangers and joint bookrunners in connection with a $5 billion five-year credit facility for Abbott Laboratories. The Shearman & Sterling team included partner Maura O’Sullivan (New York-Finance), counsel Susan Hobart (New York-Finance) and associate Spencer Barrowes (New York-Finance).
More >>

Tags:  Shearman & Sterling LLP

DLA Piper Advises on $1.65 Billion Nigerian Oil and Gas Acquisition

DLA Piper has advised Oando, the Nigeria-based integrated energy solutions provider, on the $1.65 billion acquisition of ConocoPhillips’ offshore and onshore assets in Nigeria and the associated reserve-based, multi-source financing.

This acquisition will make Oando one of the largest indigenous oil producers both in Nigeria and Africa as a whole.

More >>

Tags:  DLA Piper

Drew & Napier acted for Swissco Holdings Limited’s proposed acquisition of Scott and English Energy Pte. Ltd. for a purchase consideration of S$285 million

Drew & Napier is acted for Swissco Holdings Limited, in relation to its proposed acquisition of Scott and English Energy Pte. Ltd., a fast-growing international rig owner, for a purchase consideration of S$285 million to be satisfied by the allotment and issue of shares in Swissco Holdings Limited.

More >>

Tags:  Drew & Napier LLC

Kirkland & Ellis Represents Pfizer in $635M Acquisition of Baxter Vaccine Portfolio

Kirkland & Ellis LLP represented Pfizer Inc. in its definitive agreement announced today to acquire Baxter International Inc.’s portfolio of marketed vaccines for $635 million. As part of the transaction, Pfizer will also acquire a portion of Baxter’s facility in Orth, Austria, where these vaccines are manufactured. Baxter’s portfolio of marketed vaccines consists of NeisVac-C and FSME-IMMUN/TicoVac. The transaction is subject to customary closing conditions as well as regulatory approvals in several markets, including some countries in the European Union, and is expected to occur by the end of 2014.

More >>

Tags:  Kirkland & Ellis LLP